JP Morgan Chase’s OptimizeRx OPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding OPRX
WCA
RA
KCM
RHJA
PHP
JP Morgan Chase's OPRX Position: Q2 2026 in Review
JP Morgan Chase reduced its OptimizeRx (OPRX) stake by 97% in Q2 2026, selling an estimated $41.1K and leaving 211 shares worth $1.15K. The position accounts for ﹤0.01% of the portfolio, ranked #7309.
JP Morgan Chase first reported a position in OPRX in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.4M in Q4 2022. 112 funds tracked by Wall St. Rank hold OPRX as of Q2 2026.
- JP Morgan Chase held 211 shares of OptimizeRx worth $1.15K as of Q2 2026.
- JP Morgan Chase sold 7,154 OptimizeRx shares in Q2 2026, an estimated $41.1K.
- OptimizeRx made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7309 holding.
- JP Morgan Chase first reported a position in OptimizeRx in Q4 2018 and has held it in 31 quarters since.
- JP Morgan Chase's OptimizeRx position peaked at $2.4M in Q4 2022.
- 112 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.